ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Clascoterone

Also written as “Winlevi (clascoterone) 1% cream”, “CB-03-01 cream, 1%” and “Clascoterone 5% solution”.

Its studies are mostly in Acne Vulgaris · Alopecia, led by 4 companies.

Drug pageClascoterone: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 17, 201519 company-led studies, 3 open or runningNext primary completion: Aug 7, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cassiopea SpA70 open or runningphase 3since Nov 17, 2015Nov 17, 2015none ahead
Sun Pharmaceutical Industriesits history only61 open or runningphase 4since Mar 11, 2024Mar 11, 2024none ahead
3SBioits history only32 open or runningphase 3since Apr 30, 2024Apr 30, 2024Aug 7, 2028phase 3 · NCT07457294
Intrepid Therapeuticsits history only30 open or runningphase 2since Jun 27, 2012Jun 27, 2012none ahead

Also a collaborator on its studies: Canfield Scientific and ICON Clinical Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Cassiopea SpA only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 17, 2015First studies: 2 phase 3 studies in Acne VulgarisFirst studyNCT02608476, NCT02608450
  2. Feb 10, 2016Phase 3 study in Acne VulgarisNCT02682264 · 609 enrolled · United States, Bulgaria, Georgia and more
  3. Mar 22, 2016Phase 2 study in Acne VulgarisNCT02720627 · 27 enrolled · United States, Poland
  4. Jun 18, 2018Phase 1 study in Healthy VolunteersNCT03665194 · 32 enrolled · United Kingdom
  5. Dec 9, 2018Named clascoteroneINNProposed as its International Nonproprietary Name in WHO's List 120
  6. Jun 6, 20232 phase 3 studies in AlopeciaNCT05914805, NCT05910450

TargetBeta

AR →read by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
apalutamideruleJohnson & Johnsonphase 431
darolutamideruleBayerphase 426
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 7 Cassiopea SpA leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05914805Alopecia · United States, Germany, Poland3CompletedJul 16, 2025762
NCT05910450Alopecia · United States, Georgia3CompletedJan 26, 2026703
NCT03665194Healthy Volunteers · United Kingdom1CompletedSep 12, 201832
NCT02720627Acne Vulgaris · United States, Poland2CompletedMar 21, 201827
NCT02682264Acne Vulgaris · United States, Bulgaria, Georgia and more3CompletedAug 31, 2018609
NCT02608476Acne Vulgaris · United States, Bulgaria, Georgia and more3CompletedFeb 21, 2018732
NCT02608450Acne Vulgaris · United States, Georgia, Ukraine3CompletedApr 11, 2018708

How it is read

Names in the registry

  • “Winlevi (clascoterone) 1% cream”, 3 entries
  • “CB-03-01 cream, 1%”, 3 entries
  • “Clascoterone 5% solution”, 2 entries
  • “cortexolone 17α-propionate”, 2 entries
  • “CB-03-01”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.